Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies.

Autor: Williams JN; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Dall'Era M; University of California San Francisco School of Medicine., Lim SS; Emory University, Atlanta, Georgia., Feldman CH; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Arntsen KA; Lupus and Allied Diseases Association, Inc, Verona, New York., Blazer AD; Langone Medical Center, New York, New York., Goode T; Georgetown University Medical Center, Washington, DC., Merrill JT; Oklahoma Medical Research Foundation, Oklahoma City., Sheikh S; University of North Carolina School of Medicine, Chapel Hill., Stevens AM; University of Washington School of Medicine, Seattle, and Immunology Therapeutic Area, Janssen Research & Development LLC, Spring House, Pennsylvania., Lipsky PE; RILITE Research Institute and AMPEL BioSolutions, Charlottesville, Virginia., Costenbader KH; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Jazyk: angličtina
Zdroj: Arthritis care & research [Arthritis Care Res (Hoboken)] 2022 Mar; Vol. 74 (3), pp. 420-426. Date of Electronic Publication: 2022 Jan 19.
DOI: 10.1002/acr.24474
Abstrakt: Non-White people are more likely to develop systemic lupus erythematosus (SLE) yet are underrepresented in SLE clinical trials. The efficacy and safety of drugs may be influenced by ancestry, and ancestrally diverse study populations are necessary to optimize treatments across the full spectrum of patients. However, barriers to entry into clinical trials are amplified in non-White populations. To address these issues, a conference was held in Bethesda, Maryland, from October 15-16, 2019, entitled "Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies: Overcoming the Barriers." Conference participants included people with lupus, lupus physicians, lupus clinical trialists, treatment developers from biotechnology, social scientists, patient advocacy groups, and US government representatives (The Office of Minority Health, Centers for Disease Control and Prevention, National Institutes of Health, and the Food and Drug Administration). For all these groups, the organizers of the conference purposefully included people of non-White ancestry. Decreased participation of non-White SLE patients in clinical research was evaluated through historical, societal, experiential, and pragmatic perspectives, and several interventional programs to increase non-White patient participation in SLE and non-SLE research were described and discussed. The presentations and discussions highlighted the need for changes at the societal, institutional, research team, referring physician, and patient education levels to achieve equitable ancestral representation in SLE clinical studies.
(© 2020, American College of Rheumatology.)
Databáze: MEDLINE
Externí odkaz: